🟢 Humacyte is trading 5.88% up in pre-market on October 14, 2026 with no clear catalyst

Humacyte is trading at $0.38, up 5.88% in pre-market, with no clear company-specific catalyst identified.

• Pre-market volume was not provided.
• Humacyte announced on October 12 that interim Phase 3 V012 results were accepted for presentation at ASN Kidney Week. The announcement predates this session and does not establish a reason for the rise.
• Major indices are mixed and showing only modest moves, so broad-market sentiment does not clearly explain the gain.